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abstract
PURPOSE We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell
lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized
controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients with previously
untreated NSCLC with a programmed death ligand-1 (PD-L1) tumor proportion score of at least 50% and no
sensitizing EGFR or ALK alterations. Previous analyses showed pembrolizumab significantly improved
progression-free survival and overall survival (OS).
METHODS Eligible patients were randomly assigned (1:1) to pembrolizumab (200 mg once every 3 weeks for up
to 35 cycles) or platinum-based chemotherapy. Patients in the chemotherapy group with progressive disease
could cross over to pembrolizumab. The primary end point was progression-free survival; OS was a secondary
end point.
RESULTS Three hundred five patients were randomly assigned: 154 to pembrolizumab and 151 to chemo-
therapy. Median (range) time from randomization to data cutoff (June 1, 2020) was 59.9 (55.1-68.4) months.
Among patients initially assigned to chemotherapy, 99 received subsequent anti–PD-1 or PD-L1 therapy,
representing a 66.0% effective crossover rate. Median OS was 26.3 months (95% CI, 18.3-40.4) for pem-
brolizumab and 13.4 months (9.4-18.3) for chemotherapy (hazard ratio, 0.62; 95% CI, 0.48-0.81). Kaplan-Meier
estimates of the 5-year OS rate were 31.9% for the pembrolizumab group and 16.3% for the chemotherapy
group. Thirty-nine patients received 35 cycles (ie, approximately 2 years) of pembrolizumab, 82.1% of whom
were still alive at data cutoff (approximately 5 years). Toxicity did not increase with longer treatment exposure.
CONCLUSION Pembrolizumab provides a durable, clinically meaningful long-term OS benefit versus chemo-
therapy as first-line therapy for metastatic NSCLC with PD-L1 tumor proportion score of at least 50%.
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INTRODUCTION
Historically, patients with advanced non–small-cell
lung cancer (NSCLC) have poor prognosis despite use
of platinum-based chemotherapy. For patients with
distant metastases, the 5-year relative survival rate is
low globally, being only 6.9% in the United States
between 2010 and 2016.1,2 Immunotherapy has al-
tered the treatment approach for patients with NSCLC
without oncogenic driver mutations.3 Pembrolizumab,
a monoclonal antibody against programmed death 1
(PD-1), has been shown in randomized controlled
studies to improve overall survival (OS) versus
platinum-based chemotherapy for patients with ad-
vanced or metastatic NSCLC without sensitizing EGFR
or ALK alterations when administered as monotherapy
(in patients with programmed death ligand-1 [PD-L1]–
positive NSCLC)4,5 and when administered in combi-
nation with chemotherapy (regardless of tumor PD-L1
expression).6-9
KEYNOTE-024 is a randomized, open-label, phase III
trial of pembrolizumab monotherapy versus platinum-
based chemotherapy in patients with previously un-
treated NSCLC with PD-L1 tumor proportion score
(TPS) of at least 50% and was, to our knowledge, the
first phase III study to show superiority of immuno-
therapy over platinum-based chemotherapy in the
first-line setting.10 The study demonstrated sig-
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(hazard ratio [HR], 0.50; 95% CI, 0.37 to 0.68; P, .001)
and OS (HR, 0.60; 95% CI, 0.41 to 0.89; P 5 .005) with
pembrolizumab versus chemotherapy at the second in-
terim analysis.10 OS continued to be improved for pem-
brolizumab versus chemotherapy (HR, 0.63; 95% CI,
0.47 to 0.86) in subsequent analyses.4
Five-year survival is an important landmark in cancer
treatment, but until recently there have been limited data
with this length of follow-up in patients with metastatic
NSCLC, in part because so few patients are alive at 5 years.
In KEYNOTE-001, a single-arm phase Ib study that eval-
uated pembrolizumab monotherapy in patients with ad-
vanced NSCLC, the 5-year OS rate was 29.6% (95% CI, 7.7
to 56.1) among previously untreated patients with PD-L1




As previously described,4,10 eligible patients were $ 18
years with previously untreated stage IV NSCLC with PD-L1
TPS of at least 50%, measurable disease by RECIST v1.1,
Eastern Cooperative Oncology Group performance status of
0 or 1, and life expectancy of at least 3 months.4,10 Patients
with sensitizing EGFR or ALK alterations, untreated brain
metastases, or active autoimmune disease requiring sys-
temic treatment or receiving systemic glucocorticoids or
immunosuppressive therapy were excluded.
The Protocol was approved by institutional review boards or
independent ethics committees at participating institutions.
Patients provided written informed consent.
Study Design
Patients were randomly assigned (1:1) to receive 200 mg
of intravenous pembrolizumab once every 3 weeks for 35
cycles or investigator’s choice of platinum chemotherapy
(carboplatin/cisplatin) plus pemetrexed or gemcitabine,
or carboplatin plus paclitaxel for 4 to 6 cycles.10
Pemetrexed was permitted only for patients with non-
squamous tumors and could be administered as main-
tenance therapy. Random assignment was stratified by
Eastern Cooperative Oncology Group performance status
(0 or 1), histology (squamous or nonsquamous), and
region (East Asian or non–East Asian enrollment).
Treatment continued for the specified number of cycles
until progressive disease (PD; per RECIST v1.1), adverse
events (AEs) of unacceptable severity, or patient with-
drawal. Patients with PD were permitted to continue
study treatment if the investigator determined the patient
to be clinically stable and deriving benefit. Patients in the
chemotherapy group could cross over to receive pem-
brolizumab 30 days after the last chemotherapy dose if
safety eligibility criteria were met per the study Protocol
(online only): patients with PD confirmed by blinded,
independent central review (BICR) were eligible to cross
over before the second interim analysis; after the second
interim analysis, investigator-assessed PD was
required.10
Patients were eligible for a second course of pem-
brolizumab (up to 17 cycles) if PD occurred after com-
pletion of 35 cycles of pembrolizumab or after attaining
confirmed complete response (CR) with at least 6 months
of treatment and an additional two cycles of pem-
brolizumab after CR was achieved and anticancer therapy
had not been administered since their last dose of pem-
brolizumab and Protocol-specified eligibility criteria were
met (see the Protocol).
The primary end point was PFS (time from randomization to
disease progression or death from any cause, whichever
occurred first, per RECIST v1.1 by BICR). Secondary end
points included evaluation of OS (time from randomization
to death from any cause), objective response rate (ORR)
per RECIST v1.1 by BICR, safety, and tolerability. Both PFS
CONTEXT
Key Objective
Patients with metastatic non–small-cell lung cancer (NSCLC) have a poor prognosis. We examined whether first-line
treatment with pembrolizumab, an anti–programmed death 1 antibody, continued to provide improved long-term
outcomes over platinum-based chemotherapy in patients with programmed death ligand-1 (PD-L1) tumor proportion
score (TPS) $ 50%, without EGFR or ALK alterations.
Knowledge Generated
Patients treated with pembrolizumab had improved 5-year overall survival rates compared with patients treated with
platinum-based chemotherapy (31.9% v 16.3%).
Relevance
Pembrolizumab continues to provide long-term improved patient outcomes over chemotherapy for patients with metastatic
NSCLC with PD-L1 TPS $ 50% in the first-line treatment setting.
2 © 2021 by American Society of Clinical Oncology
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and ORR are reported by investigator review because
evaluation by BICR was discontinued after the second
interim analysis (Protocol amendment 8). The exploratory
end point PFS2, per RECIST v1.1 by investigator, was
defined as time from randomization to subsequent disease
progression after initiation of new anticancer therapy or
death from any cause.
Assessments
PD-L1 expression levels and AEs were assessed as pre-
viously described.10 Imaging was performed every 9 weeks
during the treatment phase (including during second-
course treatment) and every 3 months during the follow-
up phase, and patients were contacted every 2 months
during survival follow-up.
Statistical Analysis
Efficacy was assessed in the intention-to-treat population
and safety in the as-treated population (patients who were
randomly assigned and received at least one dose of study
treatment, analyzed by treatment received). The study
Protocol provided for one planned analysis of ORR and
PFS and two planned analyses of OS. Exploratory analyses
included outcomes in patients who completed 35 cycles
of pembrolizumab and patients who received a second
course of pembrolizumab. Superiority of pembrolizumab
over chemotherapy for PFS and OS was determined
during the second interim analysis.10 The prespecified
alpha was used at the second interim analysis. No alpha
was assigned to the current analysis. The Kaplan-Meier
method was used to estimate OS, PFS, and PFS2 as
previously described.4,10 A stratified Cox model with
Efron’s method of tie handling was used to determine HRs
and 95% CIs; randomization stratification factors were
applied to the Cox models.
RESULTS
Patient Characteristics and Treatment
A total of 305 patients were enrolled and randomly assigned
to receive pembrolizumab monotherapy (n 5 154) or
chemotherapy (n 5 151; Fig 1). All patients except one in
the chemotherapy group received study treatment. Median
time from randomization to data cutoff (June 1, 2020) was
59.9 months (range, 55.1-68.4 months). Median treatment
durations were 7.9 months (range, 1 day-30.2 months) for
the pembrolizumab group and 3.5 months (1 day-40.4
months) for the chemotherapy group. At data cutoff, no
patients were continuing to receive their initially assigned
study treatment. Among patients initially assigned to
chemotherapy, 99 received anti‒PD-1 or PD-L1 (PD-[L]1)
therapy (83 crossed over to pembrolizumab on-study, and
16 additional patients received anti‒PD-(L)1 therapy out-
side the study), representing a 66.0% effective crossover
rate. In the pembrolizumab group, 80 of 154 (52.9%)
received additional anticancer therapy, including 12 pa-
tients who received a second course of pembrolizumab on
study. Subsequent therapies for both treatment groups are
summarized in Appendix Table A1 (online only). Patient
demographics and baseline clinical characteristics are
described in Table 1.
Efficacy Outcomes in the Intention-to-Treat Population
At data cutoff, 103 patients (66.9%) in the pembrolizumab
group and 123 patients (81.5%) in the chemotherapy
group had died. Median OS was 26.3 months (95% CI,
18.3 to 40.4 months) in the pembrolizumab group and
13.4 months (95% CI, 9.4 to 18.3 months) in the che-
motherapy group (HR, 0.62; 95% CI, 0.48 to 0.81; Fig 2A).
Kaplan-Meier estimates of OS at 5 years were 31.9% (95%
CI, 24.5 to 39.5) in the pembrolizumab group and 16.3%
(95% CI, 10.6 to 23.0) in the chemotherapy group.
In addition to patients who had CR or partial response (PR),
patients who had stable disease (SD) also had OS benefit.
In an exploratory analysis, median OS among patients with
best response of SD was 21.1 months (95% CI, 14.1 to
34.5) for the pembrolizumab group and 14.5 months (95%
CI, 8.9 to 21.1) for the chemotherapy group. In a further
exploratory analysis, median OS for patients in the pem-
brolizumab group with treatment-related AEs leading to
treatment discontinuation (n5 21) was 35.9 months (95%
CI, 7.9 to NR) with a 5-year OS rate of 35.1% (95% CI, 15.7
to 55.3).
At data cutoff, 126 patients (81.8%) in the pembrolizumab
group and 141 patients (93.4%) in the chemotherapy
group had progressed per investigator assessment or died.
Median PFS was 7.7 months (95% CI, 6.1 to 10.2 months)
for patients in the pembrolizumab group versus 5.5 months
(95% CI, 4.2 to 6.2 months) for patients in the chemo-
therapy group (HR, 0.50; 95% CI, 0.39 to 0.65; Fig 2B).
Kaplan-Meier estimates of PFS at 3 and 5 years were
22.8% (95% CI, 16.3 to 29.9) and 12.8% (95% CI, 7.4 to
19.8), respectively, in the pembrolizumab group and 4.1%
(95% CI, 1.3 to 9.4) and not reached (no evaluable pa-
tients) in the chemotherapy group.
The ORR by investigator review was 46.1% (71 of 154;
95% CI, 38.1 to 54.3) among patients in the pem-
brolizumab group versus 31.1% (47 of 151; 95% CI, 23.8
to 39.2) in the chemotherapy group (Table 2). Seven pa-
tients (4.5%) in the pembrolizumab group versus no pa-
tients in the chemotherapy group achieved a CR (Table 2).
Median duration of response was 29.1 months (range,
2.2-60.81 months) in the pembrolizumab group and
6.3 months (range, 3.1-52.4 months) in the chemotherapy
group (1 indicates the response duration is censored).
Median PFS2 (time from randomization to subsequent
disease progression after initiation of new anticancer
therapy or death from any cause) was 24.1 months (95%
CI, 15.0 to 31.4 months) in patients initially randomly
assigned to pembrolizumab and 8.5 months (95% CI, 7.3
to 11.4 months) in patients initially randomly assigned to
chemotherapy (HR, 0.51; 95% CI, 0.39 to 0.67). The
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PFS2 rate at 3 years was 39.5% (95% CI, 31.4 to 47.4) for
pembrolizumab and 15.0% (95% CI, 9.4 to 21.8) for
chemotherapy (Fig 3).
Safety
No new safety signals were identified since prior analyses.
Incidence of treatment-related AEs was 76.6% (grade 3-5,
31.2%) among patients who received pembrolizumab and
90.0% (grade 3-5, 53.3%) among patients who received
chemotherapy (Table 3). Serious treatment-related AEs
occurred in 22.7% and 20.7% of patients in the pem-
brolizumab and chemotherapy groups, respectively. There
were two treatment-related deaths in the pembrolizumab
group and three in the chemotherapy group (pem-
brolizumab: sudden death of unknown cause and pneu-
monitis; chemotherapy: pulmonary sepsis, pulmonary
alveolar hemorrhage, and death of unknown cause; all
previously reported).4,10
Immune-mediated AEs and infusion reactions (irrespective
of attribution to study treatment by the investigator) oc-
curred in 34.4% (grade 3-5, 13.6%) of patients who re-
ceived pembrolizumab and 5.3% (grade 3-5, 0.7%) of
those who received chemotherapy (Table 3).
There were no new safety signals identified with long-term
follow-up. Exposure-adjusted AE rates in the total study
population decreased over time in both treatment groups
for treatment-related AEs and immune-mediated AEs and
infusion reactions (Appendix Tables A2 and A3, online
only).
Outcomes in Patients Who Completed 35 Cycles
of Pembrolizumab
Among the patients initially assigned to pembrolizumab, 39
of 151 (25.8%) completed 35 cycles (ie, approximately 2
years) of treatment. Median (range) time from completion
of 35 cycles to data cutoff was 34.7 months (31.2-44.1).





Excluded                                                 (n = 1,629)
      No sample for PD-L1 assessment      (n = 205)
      Nonevaluable sample for PD-L1          (n = 76)
      PD-L1 TPS < 50%                              (n = 1,153)
      Did not meet other eligibility             (n = 195) 
        criteria or did not participate     
Pembrolizumab group
Allocated                              (n = 154)
Treated                                 (n = 154)
Chemotherapy group
Allocated                             (n = 151)
Treated                                (n = 150)
Received subsequent anti–PD-(L)1 therapy
(66.0% effective crossover rate; n = 99)
    Crossed over to pembrolizumab           (n = 83) 
      on study 
    Additional patients received                  (n = 16) 
      anti–PD-(L)1 therapy outside the study 
Received subsequent anticancer          (n = 80)
  therapy (51.9%) 
Received second course of                   (n = 12)
  pembrolizumab 
Completed treatmenta         (n = 34)
Discontinued                      (n = 120)
    PD                                      (n = 72)
    AE                                      (n = 31)
    Patient withdrawal             (n = 7)
    Death                                   (n = 6)
    Complete response            (n = 2)
    Physician decision              (n = 1)
    Noncompliance                  (n = 1)
Completed treatmenta          (n = 29)
Discontinued                       (n = 121)
     PD                                     (n = 77)
     AE                                     (n = 18)
     Patient withdrawal            (n = 6)
     Death                                  (n = 9)
     Physician decision          (n = 11)
FIG 1. Disposition of patients. aNumber of patients who completed treatment, as reported by investigator. AE,
adverse event; PD, progressive disease; PD-L1, programmed death ligand-1; TPS, tumor proportion score.
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total study population (Table 1). Among these patients,
82.1% experienced a response, per RECIST v1.1 per in-
vestigator assessment (Fig 4A). Best response was CR in
four patients (10.3%), PR in 28 (71.8%), SD in six (15.4%),
and PD in one (2.6%). At data cutoff, 32 of 39 patients were
alive and the OS rate at 36 months from completion of 35
cycles of pembrolizumab (ie, approximately 5 years) was
81.4% (95% CI, 64.7 to 90.7). Of 39 patients, 18 (46.2%)
were alive without PD or subsequent therapy for NSCLC.
One patient developed a second malignancy (gastric
cancer) and was treated accordingly.
Among patients who completed 35 cycles, treatment-
related AEs occurred in 87.2% (grade 3-4, 15.4%; no
grade 5 events), which was consistent with the overall as-
treated population. Treatment-related grade 3-4 AEs
were diarrhea, autoimmune hepatitis, increased gamma-
glutamyltransferase, hyperglycemia, type 2 diabetes mel-
litus, tubulointerstitial nephritis, and rash (all n 5 1).
Consistent with the all patients as-treated population, in-
cidence of immune-mediated AEs and infusion reactions
was 30.8%, with grade 3-4 comprising 7.7% (one each of
hepatitis, nephritis, and severe skin toxicity) and no grade 5
events.
Outcomes Among Patients Who Received a Second
Course of Pembrolizumab
Twelve patients received a second course of pem-
brolizumab after an assessment of PD by the investigator.
Median (range) time from last dose of second course to
data cutoff was 15.2 months (0.4-29.6). Among these 12
patients, eight (66.7%) were alive at data cutoff. Four
(33.3%) had an objective response after starting second-
course pembrolizumab (all PRs) and six (50.0%) had SD as
their best response per investigator assessment (Fig 4B).
One patient experienced PD after receiving a second
course of pembrolizumab, and one patient was not
evaluable. At data cutoff, five patients (41.7%) were alive
without PD and three (25.0%) had not received subse-
quent therapy. Five patients (41.7%) had treatment-related
AEs during the second course; all were grade 1 or 2 and one






35 Cycles of Pembrolizumab,
n 5 39a
Second Course of Pembrolizumab,
n 5 12b
Age, median (range), years 64.5 (33-90) 66.0 (38-85) 61.0 (43-80) 60.0 (43-77)
Sex
Male 92 (59.7) 95 (62.9) 25 (64.1) 8 (66.7)
Female 62 (40.3) 56 (37.1) 14 (35.9) 4 (33.3)
ECOG performance status
0 54 (35.1) 53 (35.1) 16 (41.0) 3 (25.0)
1 99 (64.3) 98 (64.9) 23 (59.0) 9 (75.0)
2 1 (0.6) 0 (0.0) 0 0 (0.0)
Region of enrollment
East Asia 21 (13.6) 19 (12.6) 8 (20.5) 3 (25.0)
Non–East Asia 133 (86.4) 132 (87.4) 31 (79.5) 9 (75.0)
Histology
Squamous 29 (18.8) 27 (17.9)c 2 (5.1) 1 (8.3)
Nonsquamous 125 (81.2) 124 (82.1) 37 (94.9) 11 (91.7)
Smoking status
Current 34 (22.1) 31 (20.5) 8 (20.5) 2 (16.7)
Former 115 (74.7) 101 (66.9) 29 (74.4) 10 (83.3)
Never 5 (3.2) 19 (12.6) 2 (5.1) 0 (0.0)
Treated brain metastases 18 (11.7) 10 (6.6) 9 (23.1) 1 (8.3)
Prior neoadjuvant therapy 3 (1.9) 1 (0.7) 0 0
Prior adjuvant therapy 6 (3.9) 3 (2.0) 0 0
NOTE. Values are presented as No. (%) unless noted otherwise.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
aIncludes only those patients initially allocated to pembrolizumab who received 35 cycles of pembrolizumab according to actual exposure assessment.
bIncludes only those patients initially allocated to pembrolizumab who received a second course of pembrolizumab therapy according to actual exposure
assessment.
cIncludes patients with squamous cell carcinoma and poorly differentiated squamous cell carcinoma.
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event, grade 1 hypothyroidism, was an immune-mediated
AE.
DISCUSSION
First-line pembrolizumab monotherapy produced clinically
meaningful improvements in OS, PFS, ORR, and durable
responses versus platinum-based chemotherapy among
patients with metastatic NSCLC with PD-L1 TPS of at least
50% without sensitizing EGFR or ALK alterations. Notably,
the 5-year OS rate in the pembrolizumab group (31.9%)
was approximately double that in the chemotherapy group
(16.3%), and median OS was more than 1 year longer in
the pembrolizumab group (26.3 months) than in the
chemotherapy group (13.4 months; HR, 0.62; 95% CI,
0.48‒0.81). In addition to those with an objective response,
pembrolizumab also improved OS among patients with a
best-response assessment of SD. These data confirm the 5-
year OS outcomes in the single-arm KEYNOTE-001 study
among previously untreated patients with PD-L1 TPS of at
least 50% and represent a clinically meaningful improve-
ment in survival for patients whose prognosis has histori-
cally been very poor.1,11





















26.3 (18.3 to 40.4)
13.4 (9.4 to 18.3)
No. at risk:
154 121 106 89 78 73 66 62
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FIG 2. Kaplan-Meier estimates of (A) OS and (B) PFS in the pembrolizumab group and the chemotherapy group. For
each treatment group, the Kaplan-Meier method was used to estimate OS and PFS, with censoring of data for
patients alive or lost to follow-up at the time of last contact for OS or without disease progression or death at last
disease assessment without documented disease progression prior to initiation of second-line therapy for PFS. Tick
marks indicate censoring times. HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free
survival.
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The magnitude of treatment effect for first-line pem-
brolizumab is notable given that the majority of patients
(66.0%) in the chemotherapy group received subsequent
anti‒PD-(L)1 therapy. This high effective crossover rate
may have reduced the observed treatment effect for
pembrolizumab versus chemotherapy given that immu-
notherapy agents (including pembrolizumab) have dem-
onstrated improved OS over chemotherapy in the second-
line or later setting.12-16 In a prior analysis, we showed
that when OS for patients in the chemotherapy group
of KEYNOTE-024 was adjusted for crossover using a
simplified 2-stage model, the HR for OS was 0.49 (95% CI,
0.34 to 0.69).4 With a doubling of the median OS and the
improvement in PFS2 among patients who received
pembrolizumab, these data continue to support a first-line
immunotherapy approach, which permits early inhibition of
PD-1 signaling, in this patient population.
The long-term efficacy of pembrolizumab was further
demonstrated by analysis of outcomes in the 39 patients
who completed 35 cycles of pembrolizumab: 82.1% of
patients were alive at data cutoff, and 46.2% were alive
without PD or subsequent therapy. These data support
duration of treatment of up to 2 years with pembrolizumab.
Analysis of outcomes for patients on a second course of
pembrolizumab showed such treatment was not only
feasible but also associated with antitumor activity. Of the
12 patients who subsequently progressed and received a
second course of pembrolizumab, two-thirds were alive at
data cutoff. Notably, five of 12 were alive without PD. These
data support pembrolizumab re-treatment upon PD.
Pembrolizumab was well-tolerated and was associated with
a lower incidence of treatment-related AEs (any-grade and
grade 3-5 toxicities) than platinum-based chemotherapy in
the as-treated population and patients who completed 35
cycles. We did not identify new safety signals with long-term
follow-up, and there was no evidence of increasing toxicity
during long-term follow-up. Additionally, analysis of pa-
tients who discontinued pembrolizumab treatment be-
cause of treatment-related AEs revealed a median OS of
35.9 months, demonstrating favorable outcomes could
occur in patients with early discontinuation because of AEs.
Among patients who completed 35 cycles of pem-
brolizumab, treatment-related AEs were similar to those



















24.1 (15.0 to 31.4)
8.5 (7.3 to 11.4)
No. at risk:
154 118 97 76 69 62 52 43



















(0.39 to 0.67)Chemotherapy 151
100 (64.9)
122 (80.8)
FIG 3. Kaplan-Meier estimates of PFS2 for each treatment group, with censoring of data at the time of last contact for
patients alive without receiving second-line therapy, stopping second-line therapy without disease progression, and
not initiating third-line therapy. Tick marks indicate censoring times. HR, hazard ratio; PFS, progression-free survival.






Objective response, No. (%) 71 (46.1) 47 (31.1)
95% CI 38.1 to 54.3 23.8 to 39.2
Best objective response, No. (%)
CR 7 (4.5) 0
PR 64 (41.6) 47 (31.1)
SD 37 (24.0) 60 (39.7)
PD 35 (22.7) 25 (16.6)
Not evaluable 0 1 (0.7)
No assessment 11 (7.1) 18 (11.9)
Time to response, median
(range), months
2.1 (1.4-14.6) 2.1 (1.1-12.2)
DOR, median (range), months 29.1 (2.2-60.81) 6.3 (3.1-52.4)
NOTE. 1 indicates response duration is censored.
Abbreviations: CR, complete response; DOR, duration of response; PD,
progressive disease; PR, partial response; SD, stable disease.
aPer RECIST v1.1 by investigator review. Data cutoff: June 1, 2020.
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TABLE 3. Adverse Eventsa
AE Pembrolizumab, n 5 154 Chemotherapy, n 5 150
Treatment-related AEsb
Any grade 118 (76.6) 135 (90.0)
Grades 3-5 48 (31.2) 80 (53.3)
Serious 35 (22.7) 31 (20.7)
Led to discontinuation 21 (13.6) 16 (10.7)
Led to death 2 (1.3) 3 (2.0)
Treatment-related AEs occurring in ‡ 10% of patients in either group Any grade Grade 3 or 4c Any grade Grade 3 or 4c
Nausea 15 (9.7) 0 65 (43.3) 3 (2.0)
Anemia 8 (5.2) 2 (1.3) 66 (44.0) 29 (19.3)
Fatigue 22 (14.3) 3 (1.9) 43 (28.7) 5 (3.3)
Decreased appetite 15 (9.7) 0 39 (26.0) 4 (2.7)
Diarrhea 25 (16.2) 6 (3.9) 21 (14.0) 2 (1.3)
Neutropenia 1 (0.6) 0 33 (22.0) 20 (13.3)
Vomiting 4 (2.6) 1 (0.6) 30 (20.0) 1 (0.7)
Pyrexia 18 (11.7) 0 9 (6.0) 0
Pruritus 20 (13.0) 0 4 (2.7) 0
Constipation 6 (3.9) 0 17 (11.3) 0
Neutrophil count decreased 1 (0.6) 0 21 (14.0) 7 (4.7)
Stomatitis 4 (2.6) 0 18 (12.0) 2 (1.3)
Blood creatinine increased 5 (3.2) 1 (0.6) 16 (10.7) 1 (0.7)
Rash 17 (11.0) 3 (1.9) 3 (2.0) 0
Platelet count decreased 0 0 18 (12.0) 10 (6.7)
WBC count decreased 1 (0.6) 0 17 (11.3) 4 (2.7)
Thrombocytopenia 0 0 16 (10.7) 8 (5.3)
AEs with possible immune etiology occurring in > 0% of patients Any grade Grade 3, 4, or 5d Any grade Grade 3, 4, or 5d
Any 53 (34.4) 21 (13.6) 8 (5.3) 1 (0.7)
Colitis 6 (3.9) 3 (1.9) 0 0
Hepatitis 2 (1.3) 2 (1.3) 0 0
Hyperthyroidism 11 (7.1) 0 2 (1.3) 0
Hypophysitis 1 (0.6) 1 (0.6) 0 0
Hypothyroidism 16 (10.4) 0 3 (2.0) 0
Infusion reactions 8 (5.2) 1 (0.6) 2 (1.3) 0
Myositis 3 (1.9) 0 0 0
Nephritis 1 (0.6) 1 (0.6) 0 0
Pancreatitis 1 (0.6) 1 (0.6) 0 0
Pneumonitis 13 (8.4) 5 (3.2) 1 (0.7) 1 (0.7)
Severe skin toxicity 6 (3.9) 6 (3.9) 0 0
Thyroiditis 4 (2.6) 0 0 0
Type 1 diabetes mellitus 1 (0.6) 1 (0.6) 0 0
Uveitis 1 (0.6) 1 (0.6) 0 0
NOTE. All values are presented as No. (%).
Abbreviation: AE, adverse event.
aAEs occurring from randomization to 30 days after final dose of initially assigned treatment (90 days for serious AEs).
bRelationship to treatment assessed by investigators.
cTwo grade 5 treatment-related AEs occurred in the pembrolizumab group (pneumonitis and sudden death) and three in the chemotherapy group
(pulmonary sepsis, death, and pulmonary alveolar hemorrhage).
dOne grade 5 immune-mediated AE occurred in the pembrolizumab group (pneumonitis); there were no grade 5 immune-mediated AEs in the
chemotherapy group.
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observed in the trial overall, with a similar incidence of
grade 3 and 4 events and no deaths. Together with im-
provements in efficacy outcomes, the lower toxicity with
pembrolizumab versus chemotherapy supports the im-
proved or maintained patient-reported quality-of-life out-
comes in the pembrolizumab group that have been
previously reported.17
KEYNOTE-024 underscores the importance of pem-
brolizumab in first-line treatment of metastatic NSCLC. In
an effort to extend the benefit of pembrolizumab to other
patient populations, the KEYNOTE-042 study showed an
OS benefit over chemotherapy in patients with advanced
NSCLC and TPS . 1% without sensitizing EGFR or ALK


























FIG 4. Treatment duration and time to response in (A) patients completing 35 cycles of pembrolizumab treatment
and (B) patients who received a second course of pembrolizumab treatment. Light red bars indicate the first course of
pembrolizumab treatment duration. Light teal bars indicate the (A) first course follow-up duration or (B) second
course of treatment duration. Follow-up was defined as the time to progression or last nonprogression assessment by
investigator. Response was assessed by RECIST version 1.1 per investigator review. The maximum treatment
duration for the second course was 17 cycles. aPatient developed a secondary malignancy. CR, complete response;
NE, nonevaluable; PD, progressive disease; PR, partial response; SD, stable disease.
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chemotherapy also showed improved OS versus placebo
plus chemotherapy for both nonsquamous (KEYNOTE-
189) and squamous (KEYNOTE-407) metastatic NSCLC
without EGFR or ALK alterations irrespective of tumor PD-
L1 expression.8,9,18,19 Studies evaluating other anti–PD-(L)1
therapies have also shown improvements in OS among
patients with advanced or metastatic NSCLC (albeit with
shorter follow-up than KEYNOTE-024), either as mono-
therapy or in combination with chemotherapy and/or
antiangiogenic or anti‒CTLA-4 agents.20-24
Epidemiologic data are beginning to show the effects of new
therapies on the lung cancer disease state. Howlader et al.
recently described a substantial decrease in lung cancer
mortality in the United States: incidence-based mortality
from 2006 to 2013 decreased annually by 3.2% for men
but improved more rapidly from 2013 to 2016, with an
annual 6.3% decrease.25 For women, incidence-based
mortality decreased by 2.3% annually from 2006 to
2014 and then by 5.9% annually from 2014 to 2016. They
concluded that this decrease in mortality was likely be-
cause of the targeted agents that became available to treat
patients with EGFR and ALK mutations (only a subset of
patients with NSCLC are in this category). Five-year out-
comes in KEYNOTE-024 suggest that availability of im-
munotherapy may result in further improvement in lung
cancer survival at the population level and that pem-
brolizumab may be transforming metastatic NSCLC into a
treatable chronic disease for patients who meet eligibility
criteria.
In summary, these 5-year outcomes from the phase III
KEYNOTE-024 study, which, to our knowledge, is the first
randomized trial evaluating pembrolizumab in this setting,
show the ability of this treatment to improve long-term
outcomes for patients with NSCLC. Pembrolizumab pro-
vided a durable and clinically relevant long-term OS benefit
versus chemotherapy as first-line therapy for metastatic
NSCLC with PD-L1 TPS of at least 50% and is a standard-
of-care therapy in this setting.
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22927 Großhansdorf, Germany; e-mail: m.reck@lungenclinic.de.
EQUAL CONTRIBUTION
M.R. and D.R.-A. contributed equally to this work.
PRIOR PRESENTATION
Presented as a late-breaking oral presentation at the European Society for
Medical Oncology Virtual Congress 2020, September 19-21, 2020.
SUPPORT




AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
Disclosures provided by the authors are available with this article at DOI
https://doi.org/10.1200/JCO.21.00174.
DATA SHARING STATEMENT
Merck Sharp & Dohme Corp (MSD), a subsidiary of Merck & Co, Inc,
Kenilworth, NJ, is committed to providing qualified scientific researchers
access to anonymized data and clinical study reports from the company’s
clinical trials for the purpose of conducting legitimate scientific research.
MSD is also obligated to protect the rights and privacy of trial participants
and, as such, has a procedure in place for evaluating and fulfilling
requests for sharing company clinical trial data with qualified external
scientific researchers. The MSD data-sharing website (available at http://
engagezone.msd.com/ds_documentation.php) outlines the process and
requirements for submitting a data request. Applications will be promptly
assessed for completeness and policy compliance. Feasible requests will
be reviewed by a committee of MSD subject matter experts to assess the
scientific validity of the request and the qualifications of the requestors.
In line with data privacy legislation, submitters of approved requests must
enter into a standard data-sharing agreement with MSD before data
access is granted. Data will be made available for request after product
approval in the United States and European Union or after product
development is discontinued. There are circumstances that may prevent
MSD from sharing requested data, including country- or region-specific
regulations. If the request is declined, it will be communicated to the
investigator. Access to genetic or exploratory biomarker data requires a
detailed, hypothesis-driven statistical analysis plan that is collaboratively
developed by the requestor and MSD subject matter experts; after
approval of the statistical analysis plan and execution of a data-sharing
agreement, MSD will either perform the proposed analyses and share the
results with the requestor or construct biomarker covariates and add them
10 © 2021 by American Society of Clinical Oncology
Reck et al
Downloaded from ascopubs.org by INSTITUTE CANCER RESEARCH on July 9, 2021 from 193.063.217.012
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
to a file with clinical data that is uploaded to an analysis portal so that the
requestor can perform the proposed analyses.
AUTHOR CONTRIBUTIONS
Conception and design: Martin Reck, Delvys Rodrı́guez-Abreu, Tibor
Cs}oszi, Mary O’Brien, M. Catherine Pietanza, Julie R. Brahmer
Provision of study materials or patients: Rina Hui, Sinead Cuffe, Suman
Rao
Collection and assembly of data: Martin Reck, Delvys Rodrı́guez-Abreu,
Andrew G. Robinson, Rina Hui, Andrea Fülöp, Maya Gottfried, Nir Peled,
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APPENDIX
TABLE A1. Subsequent Therapies
Therapy Pembrolizumab, n 5 154 Chemotherapy, n 5 151
With one or more subsequent oncologic treatment 77 (50.0)a 103 (68.2)
Alectinib 0 1 (0.7)
Antiangiogenic agent 3 (1.9) 2 (1.3)
Bevacizumab 2 (1.3) 1 (0.7)
Ramucirumab 1 (0.6) 1 (0.7)
Chemotherapy 2 (1.3) 2 (1.3)
Cyclophosphamide 1 epirubicin 1 vincristine 0 1 (0.7)
Fluorouracil 1 leucovorin calcium 1 oxaliplatin 1 (0.6) 0
Fluorouracil 1 folinic acid 1 oxaliplatin 1 (0.6) 0
Gemcitabine 1 vinorelbine tartrate 1 (0.6) 1 (0.7)
Immunotherapy 20 (13.0) 99 (65.6)
Anti-GITR monoclonal antibody (unspecified) 1 nivolumab 2 (1.3) 0
Atezolizumab 2 (1.3) 2 (1.3)
Avelumab 0 1 (0.7)
Avelumab 1 utomilumab 0 1 (0.7)
Durvalumab 1 (0.6) 0
Guadecitabine 1 pembrolizumab 1 (0.6) 0
Ipilimumab 1 nivolumab 0 1 (0.7)
Nivolumab 5 (3.2) 10 (6.6)
Pembrolizumab 11 (7.1) 12 (7.9)
Pembrolizumab (in study crossover) 0 83 (55.0)
Oncologic surgery 8 (5.2) 8 (5.3)
Platinum doublet chemotherapy with or without bevacizumab 57 (37.0) 8 (5.3)
Bevacizumab 1 carboplatin 1 paclitaxel 3 (1.9) 0
Bevacizumab 1 carboplatin 1 paclitaxel albumin 1 (0.6) 0
Bevacizumab 1 carboplatin 1 pemetrexed disodium 2 (1.3) 1 (0.7)
Bevacizumab 1 cisplatin 1 pemetrexed disodium 1 (0.6) 0
Carboplatin 1 docetaxel 0 1 (0.7)
Carboplatin 1 gemcitabine 13 (8.4) 2 (1.3)
Carboplatin 1 irinotecan hydrochloride 1 (0.6) 0
Carboplatin 1 paclitaxel 8 (5.2) 2 (1.3)
Carboplatin 1 paclitaxel albumin 2 (1.3) 1 (0.7)
Carboplatin 1 pemetrexed disodium 22 (14.3) 0
Carboplatin 1 vinorelbine tartrate 2 (1.3) 1 (0.7)
Cisplatin 1 etoposide 1 (0.6) 0
Cisplatin 1 gemcitabine 2 (1.3) 0
Cisplatin 1 paclitaxel 1 (0.6) 0
Cisplatin 1 pemetrexed disodium 7 (4.5) 0
Pemetrexed disodium 1 platinum 1 (0.6) 0
(continued on following page)
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TABLE A1. Subsequent Therapies (continued)
Therapy Pembrolizumab, n 5 154 Chemotherapy, n 5 151
Radiation therapy 14 (9.1) 6 (4.0)
Single-agent chemotherapy with or without antiangiogenic agent 31 (20.1) 43 (28.5)
Amrubicin hydrochloride 0 1 (0.7)
Bevacizumab 1 paclitaxel albumin 1 (0.6) 0
Bevacizumab 1 pemetrexed disodium 2 (1.3) 1 (0.7)
Cytarabine 1 (0.6) 0
Dexamethasone 1 docetaxel 0 1 (0.7)
Docetaxel 7 (4.5) 27 (17.9)
Docetaxel 1 ramucirumab 3 (1.9) 2 (1.3)
Gemcitabine 1 (0.6) 7 (4.6)
Gimeracil 1 oteracil potassium 1 tegafur 1 (0.6) 5 (3.3)
Irinotecan hydrochloride 0 2 (1.3)
Paclitaxel 3 (1.9) 2 (1.3)
Paclitaxel albumin 0 1 (0.7)
Paclitaxel disodium 18 (11.7) 5 (3.3)
Tegafur 1 (0.6) 0
Vinorelbine tartrate 2 (1.3) 7 (4.6)
Single-agent platinum 4 (2.6) 1 (0.7)
Carboplatin 4 (2.6) 0
Cisplatin 2 (1.3) 1 (0.7)
Targeted therapy with or without taxane 7 (4.5) 8 (5.3)
Cabozantinib 1 (0.6) 1 (0.7)
Capmatinib 0 1 (0.7)
Custirsen sodium 1 docetaxel 0 1 (0.7)
Dabrafenib mesylate 1 trametinib dimethyl sulfoxide 1 (0.6) 0
Dexamethasone 1 docetaxel 1 nintedanib 1 (0.6) 0
Docetaxel 1 nintedanib 1 (0.6) 2 (1.3)
Erlotinib hydrochloride 2 (1.3) 2 (1.3)
Luminespib mesylate 0 1 (0.7)
Osimertinib mesylate 1 (0.6) 0
Other 3 (1.9) 3 (2.0)
Cabazitaxel 1 (0.6) 0
Cytarabine 1 daunorubicin 1 prednisone 1 thioguanine 0 1 (0.7)
Dendritic cell vaccine (unspecified) 0 2 (1.3)
Investigational drug (unspecified) 0 1 (0.7)
Letrozole 1 (0.6) 0
Preladenant 1 (0.6) 0
aThree additional patients received a second course of pembrolizumab but no other subsequent therapy. Twelve patients received a second course of
pembrolizumab.
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TABLE A2. Exposure-Adjusted AE Rates for Most Common Treatment-Related AEs That Occurred in . 15% of Patients in Either Group
AE Pembrolizumab Chemotherapy
Diarrhea 25 (16.2) 21 (14.0)
Fatigue 22 (14.3) 43 (28.7)
Pruritus 20 (13.0) 4 (2.7)
Nausea 15 (9.7) 65 (43.3)
Decreased appetite 15 (9.7) 39 (26.0)
Anemia 8 (5.2) 66 (44.0)
Vomiting 4 (2.6) 30 (20.0)
Neutropenia 1 (0.6) 33 (22.0)
Observation period, months 0-3 3-6 6-12 . 12 0-3 3-6 6-12 . 12
Exposed at the start of interval, No. 154 115 96 66 150 101 40 15
Total exposure, person-months 412.1 318.6 472.9 663.6 387.6 209.0 140.7 65.5
Total events (rate per 100 person-months)a 317 (76.9) 114 (35.8) 97 (20.5) 77 (11.6) 827 (213.4) 143 (68.4) 96 (68.2) 7 (10.7)
Diarrhea 16 (3.9) 9 (2.8) 8 (1.7) 2 (0.3) 20 (5.2) 2 (1.0) 3 (2.1) 1 (1.5)
Fatigue 15 (3.6) 4 (1.3) 4 (0.8) 2 (0.3) 63 (16.3) 5 (2.4) 7 (5.0) 1 (1.5)
Pruritus 14 (3.4) 3 (0.9) 6 (1.3) 6 (0.9) 4 (1.0) 0 0 0
Nausea 14 (3.4) 5 (1.6) 2 (0.4) 0 90 (23.2) 16 (7.7) 14 (9.9) 1 (1.5)
Decreased appetite 11 (2.7) 3 (0.9) 1 (0.2) 0 47 (12.1) 4 (1.9) 3 (2.1) 0
Anemia 4 (1.0) 3 (0.9) 0 1 (0.2) 68 (17.5) 10 (4.8) 9 (6.4) 0
Vomiting 4 (1.0) 3 (0.9) 0 0 38 (9.8) 6 (2.9) 10 (7.1) 0
Neutropenia 1 (0.2) 1 (0.3) 1 (0.2) 0 44 (11.4) 11 (5.3) 8 (5.7) 0
NOTE. Values are presented as No. (%) unless noted otherwise.
Abbreviation: AE, adverse event.
aData show AEs and include multiple occurrences of events. Data cutoff: June 1, 2020.
TABLE A3. Exposure-Adjusted AE Rates for Most Common Immune-Mediated AEs That Occurred in . 5% of Patients in Either Group
AE Pembrolizumab Chemotherapy
Hypothyroidism 16 (10.4) 3 (2.0)
Pneumonitis 13 (8.4) 1 (0.7)
Hyperthyroidism 11 (7.1) 2 (1.3)
Observation period, months 0-3 3-6 6-12 . 12 0-3 3-6 6-12 . 12
Exposed at the start of interval, No. 154 115 96 66 150 101 40 15
Total exposure, person-months 412.1 318.6 472.9 663.6 387.6 209.0 140.7 65.5
Total events (rate per 100 person-months)a 42 (10.2) 13 (4.1) 12 (2.5) 10 (1.5) 8 (2.1) 1 (0.5) 1 (0.7) 0
Hypothyroidism 9 (2.2) 6 (1.9) 0 1 (0.2) 3 (0.8) 0 0 0
Pneumonitis 6 (1.5) 2 (0.6) 4 (0.8) 2 (0.3) 1 (0.3) 0 0 0
Hyperthyroidism 10 (2.4) 1 (0.3) 1 (0.2) 0 1 (0.3) 1 (0.5) 1 (0.7) 0
NOTE. Values are presented as No. (%) unless noted otherwise.
Abbreviation: AE, adverse event.
aData show AEs and include multiple occurrences of events. Data cutoff: June 1, 2020.
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